Back to today’s briefing

Story perspectives

Novo Nordisk CEO Change Triggers 21% Stock Plunge

7/30/2025

49 6

Summary

Story summary

Novo Nordisk appointed Maziar Mike Doustdar as CEO on August 7, replacing Lars Fruergaard Jørgensen.
The company revised its 2025 sales growth forecast down to 8%-14% due to heightened competition and declining U.S. sales of Wegovy and Ozempic.
Following the announcement, shares fell over 21%, representing the steepest drop since the 1980s.

History

Historical Context

In 1982, the FDA approved the first synthetic insulin, transforming diabetes care. Novo Nordisk, a leader in this field, has faced challenges recently, reporting a 21% drop in shares after CEO Maziar Mike Doustdar's appointment and a revised sales forecast. This decline highlights intensified competition and potential impacts on the company's long-term strategies amid evolving market dynamics.

1 of 2

Story summary

Novo Nordisk appointed Maziar Mike Doustdar as CEO on August 7, replacing Lars Fruergaard Jørgensen.
The company revised its 2025 sales growth forecast down to 8%-14% due to heightened competition and declining U.S. sales of Wegovy and Ozempic.
Following the announcement, shares fell over 21%, representing the steepest drop since the 1980s.

1 / 2